FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies

Drug therapy, including chemotherapy, targeted therapy, immunotherapy, and endocrine therapy, stands as the foremost therapeutic approach for contemporary human malignancies. However, increasing drug resistance during antineoplastic therapy has become a substantial barrier to favorable outcomes in cancer patients. To enhance the effectiveness of different cancer therapies, an in-depth understanding of the unique mechanisms underlying tumor drug resistance and the subsequent surmounting of antitumor drug resistance is required. Recently, F-box and WD Repeat Domain-containing-7 (FBXW7), a recognized tumor suppressor, has been found to be highly associated with tumor therapy resistance. This review provides a comprehensive summary of the underlying mechanisms through which FBXW7 facilitates the development of drug resistance in cancer. Additionally, this review elucidates the role of FBXW7 in therapeutic resistance of various types of human tumors. The strategies and challenges implicated in overcoming tumor therapy resistance by targeting FBXW7 are also discussed

A Novel Cycle Slips Detection and Repair Method with AR Model of BDS-3 Dual-Frequency Signal in Severe Multipath Environments

High-level applications of geo-processing services generally lack accurate temporal and spatial information. BDS-3 provides high precision temporal and spatial reference for geoprocessing services, but their signal is prone to cycle slips in a severe multipath environment. Aiming at the problem of the reliable detection and repair of cycle slips in BDS-3 (B1c + B2a) dual-frequency positioning in a severe multipath environment, an AR (autoregressive) model-assisted MW + GF BDS dual-frequency combined detection method (AMG method) is proposed in this research. A sliding-window autoregressive prediction strategy is introduced to correct the pseudorange observations interfered by a multipath, then an AR + MW + GF cycle slips detection model is constructed, and a cycle slips statistical completeness test index is established to verify the effectiveness of the algorithm. Six groups of cycle slips are artificially added into the different constellations and dual-frequency point phase observations of BDS-3 (B1c and B2a) in a multipath environment to demonstrate the cycle slips’ detection performance. The experimental results show that the traditional MW + GF method fails, but the proposed AMG method still maintains accurate cycle slip detection and repair capabilities. The detection success rate and repair success rate obtained by using the new method are significantly improved by 63.4%, and the cycle slips’ false detection rate and missed detection rate are reduced by 64.5% and 42.0%, respectively, even in harsh environments

POU5F1 promotes the proliferation, migration, and invasion of gastric cancer cells by reducing the ubiquitination level of TRAF6

Abstract POU5F1 plays an important role in maintaining the cancer stem cell (CSC) -like properties of gastric cancer (GC) cells. The impact of POU5F1 on the proliferation and metastasis of GC was examined, along with the potential of ATRA as a specific therapeutic agent for GC. The dysregulation of POU5F1 expression in GC tissues was analyzed using public databases and bioinformatics techniques, and the disparity in POU5F1 expression between normal gastric tissues and GC tissues was further assessed through western blot, RT-qPCR, and immunohistochemistry. The present study aimed to investigate the impact of POU5F1 on the proliferation, migration, and invasion of GC cells through both in vivo and in vitro experiments. Additionally, the effects of ATRA on the proliferation, migration, and invasion of GC cells were examined using in vivo and in vitro approaches. Our findings revealed a significant upregulation of POU5F1 in GC tissues, which was found to be associated with a poorer prognosis in patients with GC. Moreover, POU5F1 was observed to enhance the proliferation, migration, and invasion of GC cells in vitro, as well as promote subcutaneous tumor growth and lung metastasis of GC cells in vivo. The overexpression of POU5F1 mechanistically triggers the process of Epithelial-mesenchymal transition (EMT) by down-regulating E-Cadherin and up-regulating N-Cadherin and VIM. POU5F1 hinders the ubiquitination of TRAF6 through negative regulation of TRIM59, thereby facilitating the activation of the NF-κB pathway. Furthermore, the administration of ATRA effectively impedes the proliferation, migration, and invasion of GC cells by suppressing the expression of POU5F1. The upregulation of POU5F1 elicits EMT, fosters the initiation of the NF-κB signaling pathway in GC cells, and stimulates the proliferation, invasion, and metastasis of GC cells. All-trans retinoic acid (ATRA) can impede these POU5F1-induced effects, thereby potentially serving as an adjunctive therapeutic approach for GC

Iron-Based Composite Oxide Catalysts Tuned by CTAB Exhibit Superior NH3–SCR Performance

Iron-based oxide catalysts for the NH3–SCR (selective catalytic reduction of NOx by NH3) reaction have gained attention due to their high catalytic activity and structural adjustability. In this work, iron–niobium, iron–titanate and iron–molybdenum composite oxides were synthesized by a co-precipitation method with or without the assistance of hexadecyl trimethyl ammonium bromide (CTAB). The catalysts synthesized with the assistance of CTAB (FeM0.3Ox-C, M = Nb, Ti, Mo) showed superior SCR performance in an operating temperature range from 150 °C to 400 °C compared to those without CTAB addition (FeM0.3Ox, M = Nb, Ti, Mo). To reveal such enhancement, the catalysts were characterized by N2-physisorption, XRD (Powder X-ray diffraction), NH3-TPD (temperature-programmed desorption of ammonia), DRIFTS (Diffuse Reflectance Infrared Fourier Transform Spectroscopy), XPS (X-ray Photoelectron Spectroscopy), and H2-TPR (H2-Total Physical Response). It was found that the crystalline phase of Fe2O3 formed was influenced by the presence of CTAB in the preparation process, which favored the formation of crystalline γ-Fe2O3. Owing to the changed structure, the redox-acid properties of FeM0.3Ox-C catalysts were modified, with higher exposure of acid sites and improved ability of NO oxidation to NO2 at low-temperature, both of which also contributed to the improvement of NOx conversion. In addition, the weakened redox ability of Fe prevented the over-oxidation of NH3, thus accounting for the greatly improved high-temperature activity as well as N2 selectivity

Iron-Based Composite Oxide Catalysts Tuned by CTAB Exhibit Superior NH₃–SCR Performance

Iron-based oxide catalysts for the NH3–SCR (selective catalytic reduction of NOx by NH3) reaction have gained attention due to their high catalytic activity and structural adjustability. In this work, iron–niobium, iron–titanate and iron–molybdenum composite oxides were synthesized by a co-precipitation method with or without the assistance of hexadecyl trimethyl ammonium bromide (CTAB). The catalysts synthesized with the assistance of CTAB (FeM0.3Ox-C, M = Nb, Ti, Mo) showed superior SCR performance in an operating temperature range from 150 °C to 400 °C compared to those without CTAB addition (FeM0.3Ox, M = Nb, Ti, Mo). To reveal such enhancement, the catalysts were characterized by N2-physisorption, XRD (Powder X-ray diffraction), NH3-TPD (temperature-programmed desorption of ammonia), DRIFTS (Diffuse Reflectance Infrared Fourier Transform Spectroscopy), XPS (X-ray Photoelectron Spectroscopy), and H2-TPR (H2-Total Physical Response). It was found that the crystalline phase of Fe2O3 formed was influenced by the presence of CTAB in the preparation process, which favored the formation of crystalline γ-Fe2O3. Owing to the changed structure, the redox-acid properties of FeM0.3Ox-C catalysts were modified, with higher exposure of acid sites and improved ability of NO oxidation to NO2 at low-temperature, both of which also contributed to the improvement of NOx conversion. In addition, the weakened redox ability of Fe prevented the over-oxidation of NH3, thus accounting for the greatly improved high-temperature activity as well as N2 selectivity

Frosted Slides Decorated with Silica Nanowires for Detecting Circulating Tumor Cells from Prostate Cancer Patients

Developing low-cost and highly efficient nanobiochips are important for liquid biopsies, real-time monitoring, and precision medicine. By in situ growth of silica nanowires on a commercial frosted slide, we develop a biochip for effective circulating tumor cells (CTCs) detection after modifying epithelial cell adhesion molecule antibody (anti-EpCAM). The biochip shows the specificity and high capture efficiency of 85.4 ± 8.3% for prostate cancer cell line (PC-3). The microsized frosted slides and silica nanowires allow enhanced efficiency in capture EpCAM positive cells by synergistic topographic interactions. And the capture efficiency of biochip increased with the increase of silica nanowires length on frosted slide. The biochip shows that micro/nanocomposite structures improve the capture efficiency of PC-3 more than 70% toward plain slide. Furthermore, the nanobiochip has been successfully applied to identify CTCs from whole blood specimens of prostate cancer patients. Thus, this frosted slide-based biochip may provide a cheap and effective way of clinical monitoring of CTCs

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro- N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N 4-(2-(isopropylsulfonyl) phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials

The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients. © 2013 American Chemical Society